10-K · February 13, 2026
10x Genomics reported revenue of $642.8 million for the year ended December 31, 2025, a 5% increase from $610.8 million in 2024, while narrowing its net loss to $43.5 million from $182.6 million a year earlier. The…
Earnings analysis · 10-Q
TXG earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
10x Genomics reported Q1 2026 results with revenue of $150.843 million, a slight decline of 3% YoY but exceeded estimates by 0.03%. EPS stood at -$0.10, matching analysts' expectations while the gross margin improved to…
Read full summary
10x Genomics reported Q1 2026 results with revenue of $150.843 million, a slight decline of 3% YoY but exceeded estimates by 0.03%. EPS stood at -$0.10, matching analysts' expectations while the gross margin improved to 70% due to lower costs. The company retains full-year revenue expectations of $600 to $625 million, expecting moderate growth, excluding one-time revenues from the previous year.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.1
- Gross margin
- 70%
What stood out
-
Revenue Exceeds Estimates
Actual revenue was $150.843 million, surpassing estimates of $146.381 million by 3.05%.
-
Gross Margin Improvement
The gross margin improved to 70%, up from 68% in Q1 2025.
-
Reduction in Operating Loss
Operating expenses decreased by 15% year over year, from $144.773 million to $123.224 million.
-
Increase in Consumables Revenue
Consumables revenue grew by 13% to $129.801 million, compared to $115.356 million last year.
-
Strong Cash Position
Cash and cash equivalents rose by $16.4 million to $539.8 million, as of March 31, 2026.
-
Positive Operating Cash Flow
Operating cash flow was $26.120 million, although lower than $34.351 million from the previous year.
What to watch
-
Ongoing Net Loss
The company reported a net loss of $13.5 million for Q1 2026, contributing to an accumulated deficit of $1.5 billion.
-
Significant Decrease in License Revenue
License and royalty revenue declined by 94% to $947,000, down from $17.060 million due to a one-time patent settlement in 2025.
-
Dependence on Consumables for Growth
Instruments revenue plummeted by 24% to $11.262 million, indicating vulnerability if consumables growth does not sustain.
Management's outlook
Maintaining full-year revenue expectations of $600M to $625M.
Earlier filings 4
10-Q · October 29, 2024
10x Genomics reported Q3 revenue of $151,654 (in thousands), roughly flat YoY but down versus the prior quarter, while gross profit expanded to $106,393 and gross margin improved to 70.2%. Operating loss narrowed to…
10-Q · April 30, 2024
10x Genomics reported Q1 revenue of $141,006,000, up $6,721,000 (+5.0%) versus Q1 2023, but profitability deteriorated: gross profit was $92,914,000 (65.9% margin) and operating loss widened to $61,498,000. Net loss was…
10-K · February 15, 2024
10x Genomics describes a platform-driven strategy selling instruments, consumables and software (Chromium, Visium, Xenium) to capture a large share of the life sciences tools market. Revenue grew 20% year-over-year to…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.